Jenna Renee Mckinney, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 316 W 2nd St, Morehead, KY 40351 Phone: 606-784-3771 Fax: 606-783-6847 |
Dr. Jennifer Melissa Courtier, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 245 Flemingsburg Rd, Morehead, KY 40351 Phone: 606-780-5500 |
News Archive
As thousands of Americans await a life-saving kidney or liver transplant, medical teams are paying close attention to another organ: their hearts. This month the American Heart Association attempts to bring harmony to the varied cardiac evaluation policies created at U.S. hospitals that assess a patient's overall health before transplant surgery.
Merck & Co., Inc. announced today that in new Phase III data, GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] was 77.5 percent (95 percent CI: 39.6, 93.3) efficacious against anal intraepithelial neoplasia (AIN) associated with human papillomavirus (HPV) types 6, 11, 16 and 18 in 16-to-26 year-old men who have sex with men. The data were presented at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) conference in Monte Carlo, Monaco.
New findings from Bristol scientists could lead to future treatments to prevent lower limb amputations in diabetes - which currently affect 100 people a week in the UK (source Diabetes UK). The research from the University of Bristol is published online in Circulation Research and was funded by the British Heart Foundation (BHF) and the European Vascular Genomic Network of Excellence (EVGN).
The use of electronic cigarettes, battery operated devices that often look like cigarettes and deliver vaporized nicotine, is on the rise, including among minors. In a survey between 2011 and 2012, 10 percent of high school students reported ever using an e-cigarette.
The University of California, San Diego, The Salk Institute for Biological Studies and Life Technologies Corporation today announced the initiation of studies which may lead to the future development of cell transplant therapy for amyotrophic lateral sclerosis, also known as Lou Gehrig's disease. Currently, there is only one FDA-approved pharmaceutical addressing this lethal disease, which affects approximately 30,000 people in the United States.
› Verified 3 days ago